Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cannabis is one of the most widely used substances worldwide. Heavy use is associated with an increased risk of cannabis use disorders, psychotic disorders, acute cognitive impairment, traffic injuries, respiratory problems, worse pregnancy outcomes, and there are indications for genotoxic and epigenotoxic adverse effects. International regulation of medical and non-medical cannabis use is changing rapidly and substantially, highlighting the importance of robust public health monitoring. This study aimed to describe the trends of key public health indicators in European Union (27 member states + UK, Norway and Turkey) for the period 2010 to 2019, their public health implications, and to identify the steps required to improve current practice in monitoring of cannabis use and harm in Europe. METHODS: Data on four key cannabis indicators (prevalence of use, prevalence of cannabis use disorder [CUD], treatment rates, and potency of cannabis products) in Europe were extracted from the United Nations Office on Drugs and Crime, European Monitoring Centre for Drugs and Drug Addiction and the Global Burden of Disease study. For prevalence of use and CUD, the first and last available estimate in each country were compared. For treatment rates and cannabis potency, linear regression models were conducted. FINDINGS: Between 2010 and 2019, past-month prevalence of cannabis use increased by 27% in European adults (from 3·1 to 3·9%), with most pronounced relative increases observed among 35-64 year-olds. In 13 out of 26 countries, over 20% of all past-month users reported high-risk use patterns. The rate of treatment entry for cannabis problems per 100,000 adults increased from 27·0 (95% CI: 17·2 to 36·8) to 35·1 (95% CI: 23·6 to 46·7) and has mostly plateaued since 2015. Modest increases in potency were found in herbal cannabis (from 6·9% to 10·6% THC) while median THC values tripled in cannabis resin (from 7·6% to 24·1% THC). INTERPRETATION: In the past decade, cannabis use, treatment rates and potency levels have increased in Europe highlighting major concerns about the public health impact of cannabis use. Continued monitoring and efforts to improve data quality and reporting, including indicators of high-risk use and cannabis-attributable harm, will be necessary to evaluate the health impact of international changes in cannabis regulation. FUNDING: This study received no specific funding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013.
Hasin, D. S., Saha, T. D., Kerridge, B. T., Goldstein, R. B., Chou, S. P., Zhang, H., Jung, J., Pickering, R. P., Ruan, W. J., Smith, S. M., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1858 · Cited by 1,086
Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., Rodriguez, V., Jongsma, H. E., Ferraro, L., La Cascia, C., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30048-3 · Cited by 875
Self-citationCannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552 · cited 1×
“Occasional and more so heavy use of cannabis is associated with a number of adverse outcomes, including cannabis use disorder (CUD; [3]) and an increased risk of psychosis [4-7], acute cognitive impairment [8,9] as well as other outcomes such as motor vehicle accidents [10], respiratory problems, testicular cancer [11…”
BackgroundScott, J. C., Slomiak, S. T., Jones, J. D., Rosen, A. F. G., Moore, T. M., & Gur, R. C. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0335 · Cited by 391 · cited 1×
“Occasional and more so heavy use of cannabis is associated with a number of adverse outcomes, including cannabis use disorder (CUD; [3]) and an increased risk of psychosis [4-7], acute cognitive impairment [8,9] as well as other outcomes such as motor vehicle accidents [10], respiratory problems, testicular cancer [11…”
BackgroundPsychosocial interventions for cannabis use disorder
Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B., & Gowing, L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005336.pub4 · Cited by 282 · cited 1×
“Psychosocial interventions such as Motivational Interviewing and Cognitive Behavioural Therapy have been shown to be effective at reducing cannabis use [48,49].”
BackgroundAssociation of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence
Hines, L. A., Freeman, T. P., Gage, S. H., Zammit, S., Hickman, M., Cannon, M., Munafo, M., MacLeod, J., & Heron, J. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.1035 · Cited by 208 · cited 1×
“High-potency cannabis was also associated with increased risk of psychosis [75], and with frequency of use, cannabis-related problems and anxiety [76].”
BackgroundSelf-citationCampeny, E., López-Pelayo, H., Nutt, D., Blithikioti, C., Oliveras, C., Nuño, L., Maldonado, R., Florez, G., Arias, F., Fernández-Artamendi, S., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.02.003 · Cited by 127 · cited 2×
“While the underlying reasons for an aging population of cannabis users are yet to be singled out, the prolonged use of cannabis might be associated with an increase in the risk of lung cancer [62] or chronic obstructive pulmonary disease [13] both of which are rather rare among younger adults.”
BackgroundArterberry, B. J., Treloar Padovano, H., Foster, K. T., Zucker, R. A., & Hicks, B. M. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.11.012 · Cited by 103 · cited 1×
“4 times per each unit of THC [73]) and greater severity of CUD [74], especially among younger people.”
BackgroundMotivational Interviewing for Cannabis Use Disorders: A Systematic Review and Meta-Analysis
Calomarde-Gómez, C., Jiménez-Fernández, B., Balcells-Oliveró, M., Gual, A., & López-Pelayo, H. (2021) · European Addiction Research · doi:10.1159/000515667 · Cited by 60 · cited 1×
“Psychosocial interventions such as Motivational Interviewing and Cognitive Behavioural Therapy have been shown to be effective at reducing cannabis use [48,49].”
BackgroundSelf-citation
Cited by
Solmi, M., De Toffol, M., Kim, J. Y., Choi, M. J., Stubbs, B., Thompson, T., Firth, J., Miola, A., Croatto, G., Baggio, F., et al. (2023) · BMJ · doi:10.1136/bmj-2022-072348 · Cited by 271
Metadata
- Authors
- Manthey, J., Freeman, T. P., Kilian, C., López-Pelayo, H., & Rehm, J.
- Venue
- The Lancet Regional Health - Europe
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 10
- Pages
- 100227
- ISSN
- 2666-7762 (ISSN-L)
- OpenAlex
- W3201396326
- Cited by
- 184
- References
- 10
- FWCI
- 14.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates. https://app.cochat.ai/papers/10.1016/j.lanepe.2021.100227
- The paper
- Manthey, J., Freeman, T. P., Kilian, C., López-Pelayo, H., & Rehm, J. (2021). Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates. The Lancet Regional Health - Europe. https://doi.org/10.1016/j.lanepe.2021.100227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.